bg_1

BSP – Biological Signal Processing Ltd.

BSP is dedicated to providing novel, non-invasive and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease.

Using proprietary signal processing technology,  BSP’s products perform analysis of the high-frequency QRS components for more sensitive and accurate results than conventional stress testing and recently, also for resting ECG tests. The short video below describes this exciting technology.

Integration of BSP’s innovative technology into top-of-the-line stress ECG systems enables a unique solution providing superior diagnostic accuracy, while utilizing conventional stress testing protocols.

What’s New
The potential benefits of implantable HyperQ to be presented in the upcoming STAFF meeting (October 6th, Bled, Slovenia)
Phase 1 of HyperQTotal was successfully completed
Phase 1 of HyperQTotal, a Horizon 2020 project is granted
A second patent regarding the implantable technology receives notice of allowance from the USPTO
Notice of allowance from the USPTO for the first patent concerning BSP's implantable technology
Another signal processing patent is allowed by the European Patent Office
BSP receives notice of allowance from the European Patent Office for a patent regarding its signal processing technology
The HyperQ Rest system obtains FDA approval - the first product using the Resting ECG technology with 510(k) approval
BSP receives notice of allowance from the USPTO for a patent regarding its high frequency ECG technology for indicating ischemia
Office of the Chief Scientist (OCS) approves funding for continuing the development of the Resting ECG technology
BSP presented its study on continuous HyperQ monitoring at the 12th International Dead Sea Symposium (IDSS)